Sun Pharmaceutical vs Dr. Reddy’s: share price, P/E, ROE and financials compared
Sun Pharmaceutical Industries
Dr. Reddy's Laboratories
Sun Pharmaceutical and Dr. Reddy’s at a glance
Sun Pharmaceutical and Dr. Reddy’s are both listed in Healthcare. Sun Pharmaceutical is the larger by market cap, at ₹4.5L Cr against ₹1.1L Cr for Dr. Reddy’s (3.9 times as large). On valuation, Dr. Reddy’s has the lower price-to-book (2.96× against 4.99×). On returns and margins, Sun Pharmaceutical has the higher ROCE (17.9% against 14.2%), the higher ROE (13.1% against 7.3%) and the higher operating margin (28.2% against 15.9%). Over three years, Sun Pharmaceutical has faster 3-year profit growth (+10.6% against −1.7% a year), while Dr. Reddy’s has faster 3-year sales growth (+11.0% against +10.4% a year). Sun Pharmaceutical carries less debt for its equity, with a debt-to-equity of 0.04× against 0.19×.
Key metrics, side by side
| Metric | Sun PharmaceuticalSUNPHARMA | Dr. Reddy’sDRREDDY |
|---|---|---|
| Price (₹) | 1,860.00 | 1,373.00 |
| Market cap (₹ Cr) | 4,46,276 | 1,14,462 |
| P/E | 40.7× | 40.9× |
| P/B | 4.99× | 2.96× (the lower figure, shaded) |
| Dividend yield, trailing | 0.86% (the higher figure, shaded) | 0.58% |
| ROE | 13.1% (the higher figure, shaded) | 7.3% |
| ROCE | 17.9% (the higher figure, shaded) | 14.2% |
| Operating margin (OPM) | 28.2% (the higher figure, shaded) | 15.9% |
| Net margin (NPM) | 17.8% (the higher figure, shaded) | 8.5% |
| Sales CAGR 3Y | +10.4% | +11.0% (the higher figure, shaded) |
| Profit CAGR 3Y | +10.6% (the higher figure, shaded) | −1.7% |
| Debt to equity | 0.04× (the lower figure, shaded) | 0.19× |
| Interest cover | 45.6× (the higher figure, shaded) | 15.7× |
| Net profit TTM (₹ Cr) | 10,966 | 2,799 |
| 1Y return | +8.2% | +13.8% (the higher figure, shaded) |
| Promoter holding | 52.68% | – |
Sun Pharmaceutical vs Dr. Reddy’s: common questions
Which is bigger, Sun Pharmaceutical or Dr. Reddy’s?
By market cap, Sun Pharmaceutical is bigger at ₹4.5L Cr, against ₹1.1L Cr for Dr. Reddy’s (prices as of 6 Nov 2026). Net profit over the last twelve months was ₹10,966 Cr for Sun Pharmaceutical and ₹2,799 Cr for Dr. Reddy’s.
Which has a lower P/E ratio, Sun Pharmaceutical or Dr. Reddy’s?
Sun Pharmaceutical trades at a P/E of 40.7× and Dr. Reddy’s at 40.9×. The two are close. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Sun Pharmaceutical or Dr. Reddy’s?
Sun Pharmaceutical reports a return on equity of 13.1% and Dr. Reddy’s 7.3%. Sun Pharmaceutical has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Sun Pharmaceutical or Dr. Reddy’s?
Over the last three years: Sales grew +10.4% a year at Sun Pharmaceutical and +11.0% at Dr. Reddy’s, so Dr. Reddy’s grew sales faster; profit grew +10.6% a year at Sun Pharmaceutical and −1.7% at Dr. Reddy’s, so Sun Pharmaceutical grew profit faster. Past growth doesn’t predict future growth.